Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Colorectal Neoplasms 6Neoplasm Metastasis 3Squamous Cell Carcinoma of Head and Neck 1Recurrence Free Survival 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Advanced Solid Tumors 1

Interventions

Paclitaxel 16pembrolizumab 15Carboplatin 13Specimen Handling 9Magnetic Resonance Spectroscopy 8Biopsy 7Bevacizumab 7Fulvestrant 6olaparib 5Taxes 5Megestrol Acetate 5Doxorubicin 5Cisplatin 5trastuzumab deruxtecan 4dostarlimab 4Nivolumab 4Gemcitabine 4palbociclib 3durvalumab 3Progestins 3Oxaliplatin 3Medroxyprogesterone Acetate 3Leucovorin 3Letrozole 3Immunoglobulin G 3Fluorouracil 3Docetaxel 3Disulfides 3ribociclib 2pertuzumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Neoplasms × Panitumumab × 30 days × Clear all
NCT05564377 2026-06-02

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
2,900 enrolled
Gynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡